Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial

Table 1 Baseline characteristics

Baseline characteristic	Lithium (n = 23)	Placebo (n = 30)	p value
Gender
Male	n = 1 (4%)	n = 4 (13%)	0.374^e
Female	n = 22 (96%)	n = 26 (87%)
Age	37.7 ± 8.1^a years	40.8 ± 8.54^a years	0.186^c
Weight	68.5 ± 16.2^a kg	71.2 ± 12.7^a kg	0.493^c
Months on ART	33 (12–56)^b months	40 (26–68)^b months	0.262^d
Renal function
Creatinine	58 (49–62)^b µmol/L	58.5 (50–68)^b µmol/L	0.404^d
eGFR MDRD	139.3 (118.1–159.7)^b mL/min	131.0 (110.9–156.9)^b mL/min	0.572^d

eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease formula
^aMean and standard deviation
^bMedian and interquartile range
^ct-test (2 samples)
^dWilcoxon sum rank
^eFisher’s exact test

ISSN: 1742-6405